Back to Search Start Over

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer

Authors :
Ying Cheng
Hui Li
Liang Zhang
Jing-Jing Liu
Chang-Liang Yang
Shuang Zhang
Peng Lyu
Source :
Chinese Medical Journal, Vol 134, Iss 15, Pp 1780-1788 (2021)
Publication Year :
2021
Publisher :
Wolters Kluwer, 2021.

Abstract

Abstract. In recent years, immune checkpoint inhibitors (ICIs) have made breakthroughs in the field of lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor monotherapy was the first to break the treatment pattern for non-small cell lung cancer (NSCLC). However, owing to the limited benefit of ICI monotherapy at the population level and its hyper-progressive phenomenon, it may not meet clinical needs. To expand the beneficial range of immunotherapy and improve its efficacy, several research strategies have adopted the use of combination immunotherapy. At present, multiple strategies, such as PD-1/PD-L1 inhibitors combined with chemotherapy, anti-angiogenic therapy, cytotoxic T-lymphocyte-associated protein 4 inhibitors, and radiotherapy, as well as combined treatment with new target drugs, have been evaluated for clinical practice. To further understand the current status and future development direction of immunotherapy, herein, we review the recent progress of ICI combination therapies for NSCLC.

Subjects

Subjects :
Medicine

Details

Language :
English
ISSN :
03666999, 25425641, and 00000000
Volume :
134
Issue :
15
Database :
Directory of Open Access Journals
Journal :
Chinese Medical Journal
Publication Type :
Academic Journal
Accession number :
edsdoj.f5b65600c3e74ef3920ed88f336774af
Document Type :
article
Full Text :
https://doi.org/10.1097/CM9.0000000000001560